Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28345419 | 0.86 | SIGMAR1 (0.74) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL10675764 | 0.86 | SIGMAR1 (0.74) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL29941615 | 0.86 | SIGMAR1 (0.74) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL10566722 | 0.86 | SIGMAR1 (0.74) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL22528263 | 0.86 | SIGMAR1 (0.79) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL7246919 | 0.85 | GRIN2B (0.82) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL22528260 | 0.85 | SIGMAR1 (1.00) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL4944193 | 0.85 | HTR1A (0.97) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL13360954 | 0.85 | HTR1A (0.75) | SIGMAR1HTR1AGRIN2B | |
| SCHEMBL16335361 | 0.84 | SIGMAR1 (0.75) | SIGMAR1HTR1AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | SIGMAR1 664/4885HTR1A 144/4885GRIN2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.